Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy

Table 3 Association between UGT1A1*28 genotypes and response to treatment n (%)

UGT1A1*28 genotype	Complete response	Partial response	Stable disease	Progressive disease	Objective response2		Simple analysis			Multiple analysis3
					n	Yes	OR	95%CI	P value	OR	95%CI	P value
(TA)6/6	3 (3.6)	33 (39.3)	34 (40.5)	14 (16.7)	84	36 (42.9)	1.000 (ref.)			1.000 (ref.)
(TA)6/7 or (TA)7/71	1 (2.8)	5 (13.9)	18 (50.0)	12 (33.3)	36	6 (16.7)	0.267	0.100-0.709	0.008	0.244	0.088-0.678	0.007

¹In the dominant model;

²Yes, partial and complete response;

³Multiple analyses were adjusted for age, sex, KPS, histology, primary tumor site and treatment regimen. KPS: Karnofsky performance status.